

CARCINOMA PROSTATICO METASTATICO LA CARTA D'IDENTITÀ DEL PAZIENTE CANDIDABILE AI NUOVI TRATTAMENTI



Palazzo dei Congressi di Riccione




Il paziente metastatico ormonosensibile: identificazione e trattamento

Cosimo De Nunzio

UOC Urologia, Ospedale Sant'Andrea Sapienza - Università di Roma

De Novo Metastatic Prostate Cancer incidence

~6 % across Europe



Historically, and rogen deprivation therapy (ADT) has been the standard of care

1. Weiner AB, et al. Prostate Cancer Prostatic Dis. 2016;19:395-397. 2. Buzzoni C, et al. Eur Urol. 2015;68:885-890. 3. Chen R, et al. Asian J Urol. 2014;1:15-29. 4. Ito K. Nat Rev Urol. 2014;11:15-29. 5. Nardi AC. Int Braz J Urol. 2012;38:155-166. 6. Yamaoka M, et al. Clin Cancer Res. 2010;16:4319-4324

Current diagnostic paradigm is evolving:

Intermediate-risk PCa	LE	Strength rating
In predominantly Gleason pattern 4 (≥ ISUP 3), use prostate multiparametric magnetic resonance imaging (mpMRI) for local staging.	2b	Weak
In predominantly Gleason pattern 4, include at least a cross-sectional abdominopelvic imaging and bone-scan for metastatic screening.	2a	Weak

High-risk localised PCa/locally advanced PCa	LE	Strength rating
Use prostate mpMRI for local staging.	2b	Strong
Perform metastatic screening including at least cross-sectional abdominopelvic imaging and a bone-scan.	2a	Strong

TC PET PSMA can change management in about 21% of patients

EAU guidelines 2018

ADT + docetaxel: a new standard of care for men with mHNPC (high metastatic burden)

Overall Survival	ADT + DOC	ADT			
	Median (mos)	Median (mos)	HR (95% CI)	P Value	
GETUG-15 ¹	62.1	48.6	0.88 (0.68-1.14)	0.3	
CHAARTED ^{2*}	57.6	47.2	0.73 (0.59-0.89)	0.0018	
STAMPEDE ³	60	45	0.76 (0.62-0.92)	0.005	ę

Gravis G, et al. *Eur Urol*. 2016 ; Sweeney C, et al. *N Engl J Med*. 2015; James N, et al. *Lancet*. 2016;. * HVD as presence of visceral metastasis or \geq 4 bone metastases with \geq 1 beyond the vertebral bodies and pelvis 5

M+ Hormone Naive Prostate Cancer

Guidelines for hormonal treatment of metastatic prostate cancer 6.6.10.

	Recommendations	LE	GR			
	In M1 symptomatic patients, offer immediate castration to palliate symptoms and reduce the risk for potentially catastrophic sequelae of advanced disease (spinal cord compression, pathological fractures, ureteral obstruction, extra- skeletal metastasis).	1b	A			
	In M1 asymptomatic patients, offer immediate castration to defer progression to a symptomatic stage and prevent serious disease progression-related complications.	1b	A			
Offer castration	combined with abiraterone acetate plus prednisone to all patient	s who	ose	Stro	ong	
first presentation	ris M1 disease and who are fit enough for the regimen.		EA	U G	uidelines	2018
	In M1 asymptomatic patients, discuss deferred castration with a well- informed patient since it lowers the treatment side effects, provided the patient is closely monitored.	2b	В			

EAU Guidelines 2017

Hormone Sensitive Prostate Cancer

Latitude study N Engl J Med. 2017 June 4

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, M.D., Ph.D., NamPhuong Tran, M.D., Luis Fein, M.D., Nobuaki Matsubara, M.D., Alfredo Rodriguez-Antolin, M.D., Ph.D., Boris Y. Alekseev, M.D., Mustafa Özgüroğlu, M.D., Dingwei Ye, M.D., Susan Feyerabend, M.D., Andrew Protheroe, M.D., Ph.D., Peter De Porre, M.D., Thian Kheoh, Ph.D., Youn C. Park, Ph.D., Mary B. Todd, D.O., and Kim N. Chi, M.D., for the LATITUDE Investigators*

Stampede study N Engl J Med. 2017 June 3

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

N.D. James, J.S. de Bono, M.R. Spears, N.W. Clarke, M.D. Mason,
D.P. Dearnaley, A.W.S. Ritchie, C.L. Amos, C. Gilson, R.J. Jones, D. Matheson,
R. Millman, G. Attard, S. Chowdhury, W.R. Cross, S. Gillessen, C.C. Parker,
J.M. Russell, D.R. Berthold, C. Brawley, F. Adab, S. Aung, A.J. Birtle, J. Bowen,
S. Brock, P. Chakraborti, C. Ferguson, J. Gale, E. Gray, M. Hingorani, P.J. Hoskin,
J.F. Lester, Z.I. Malik, F. McKinna, N. McPhail, J. Money-Kyrle, J. O'Sullivan,
O. Parikh, A. Protheroe, A. Robinson, N.N. Srihari, C. Thomas, J. Wagstaff,
J. Wylie, A. Zarkar, M.K.B. Parmar, and M.R. Sydes, for the STAMPEDE Investigators*


Abiraterone ha ricevuto l'approvazione EMA (Nov 2017)

LATITUDE: Study Design



- Conducted at 235 sites in 34 countries in Europe, Asia-Pacific, Latin America, and Canada
- Designed and fully enrolled prior to publication of CHAARTED/STAMPEDE results

STAMPEDE Outcome measures



STAMPEDE: Abiraterone comparisons

2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 A = "900 pts --> "267 primary outcome measure events G = "900 pts


Primary outcome measure	Secondary outcome measures
Overall survival	Failure-free survival (FFS)
	Toxicity
	Quality of life
	Skeletal-related events
	Cost effectiveness
FFS definition	PSA failure definition
	PSA failure definition
First of:	PSA fall >= 50%
First of: PSA failure	PSA fall >= 50% → 24wk nadir + 50% and
PSA failure	→ 24wk nadir + 50% and
PSA failure Local failure	→ 24wk nadir + 50% and

James N, et al. ASCO 2017. LBA5003 and Oral Abstract Session

Demographics and Baseline Disease Characteristics: LATITUDE


	ADT-Abiraterone- Prednisone (n = 597)	ADT-Placebos (n = 602)
Age (yr), n (%) < 65 65–69 70–74 ≥ 75 Median (range)	221 (37) 112 (19) 141 (24) 123 (21) 68.0 (38-89)	233 (39) 134 (22) 115 (19) 120 (20) 67.0 (33-92)
Gleason score at initial diagnosis, n (%) < 7 7 ≥ 8	4 (0 7) 9 (2) 584 (98)	1 (0.2) 15 (2) 586 (97)
Baseline pain score (BPI-SF Item 3), n (%) 0-1 2-3 ≥ 4	284 (50) 123 (22) 163 (29)	288 (50) 137 (24) 154 (27)
Patients with \geq 3 bone metastases at screening, n/N (%)	586/597 (98.2)	585/602 (97.2)
Patients with high risk at screening, n (%) n Gleason score $\geq 8 + \geq 3$ bone lesions Gleason score $\geq 8 +$ measurable visceral disease ≥ 3 bone lesions + measurable visceral disease Gleason score $\geq 8 + \geq 3$ bone lesions + measurable visceral disease	597 573 (96) 82 (14) 84 (14) 71 (12)	601 569 (95) 87 (14) 85 (14) 70 (12)

In LATITUDE and STAMPEDE addition of AA+P to ADT significantly improved OS



LATITUDE¹

STAMPEDE - M1 Disease^{2,3}




 LATITUDE: 38% reduction in the risk of death in patients with NDx HR mHSPC

- STAMPEDE: **39% reduction in the risk of death** in patients with mHSPC
- 1. Fizazi K, et al. N Engl J Med. 2017 Jul 27;377(4):352-360;
- 2. James N, et al. N Engl J Med. 2017 Jul 27;377(4):338-351


In LATITUDE and STAMPEDE addition of AA+P to ADT significantly delayed progression

LATITUDE - rPFS¹



 LATITUDE: 53% reduction in the risk of radiographic progression or death in patients with NDx HR mHSPC **STAMPEDE – FFS**^{2,3}





 STAMPEDE: 69% reduction in the risk of FFS in patients with mHSPC

1. Fizazi K, et al. N Engl J Med. 2017 Jul 27;377(4):352-360

2. James N, et al. N Engl J Med. 2017 Jul 27;377(4):338-351

LATITUDE: Overall Survival by Subgroup

R 3 R 3	4.7 – 3.7 – 5.1 –		0.63 (0.51–0.76)
R 3	5.1 🛏	-	
R 3	5.1 🛏	-	
			0.62 (0.45-0.84)
R I		H :	0.64 (0.49-0.82)
	NR 🛏		0.82 (0.53-1.27)
R 3	8.2 🛏	H I	0.64 (0.48-0.86)
R 3	1.3 🛏		0.61 (0.46-0.79)
R 3	2.3		0.51 (0.33-0.79)
R 3	5.1 🛏	H	0.66 (0.53-0.83)
R I	NR 🛏 🛶		0.62 (0.18-2.11)
R 3	4.7		0.63 (0.51-0.77)
R I	NR 🛏		0.65 (0.45-0.96)
R 3	1.3 🛏	-	0.60 (0.47-0.75)
R	36 🛏		0.68 (0.51-0.89)
R 3	3.9	-	0.58 (0.44-0.77)
R 3	i3.9 ⊢		0.74 (0.56-0.96)
R 3	6.7	4	0.51 (0.38-0.69)
R I	NR 🛏	•	0.73 (0.42-1.27)
	0.5	4	0.50 (0.36-0.69)
R 3	8.1	•	0.75 (0.51-1.09)
			0.70 (0.45-1.09)
R 3	31 🛏		0.70 (0.45-1.09)

ADT-abiraterone-prednisone better ADT-placebos better

The treatment effect of ADT-abiraterone-prednisone on OS was consistently favorable across nearly all prespecified subgroups


Fizazi, Karim, et al. New England Journal of Medicine 377.4 (2017): 352-360

LATITUDE: Summary of Most Common Adverse Events and Adverse Events of Special Interest

	Adverse Event		-Abiratero		Д	DT <mark>-</mark> Placebo (n = 602)	S
		All	Gr 3	Gr 4	All	Gr 3	Gr 4
				no of p	oatients (%))	
	Hypertension	37	20	0	22	10	0.2
-/	Hypokalemia	20	10	0.8	4	1	0.2
	ALT increased	16	5	0.3	13	1	0
	Hyperglycemia	13	4	0.2	11	3	0
	AST increased	15	4	0.2	11	1	0
	Bone pain	12	3	0	15	3	0
	Cardiac disorder Atrial fibrillation	12 1	3 0.3	0.8 0	8 0.3	1 0.2	0 0
	Anemia	9	2	0.5	14	4	0.2
	Back pain	18	2	0	20	3	0
	Fatigue	13	2	0	14	2	0
	Spinal cord compression	2	2	0	2	1	0.5

Abiraterone vs Docetaxel in M+HNPCa

drogen-deprivation therapy alone or with docetaxel in	Articles
drogen-deprivation therapy alone or with docetaxel in	
n-castrate metastatic prostate cancer (GETUG-AFU 15): andomised, open-label, phase 3 trial dle Gravis, Karim Fizaz, Flarence Joly, Stephane Oudard, Frank Prior, Benjamin Esterni, Igar Latozeff, Ramy Debus, Ivan Krakowski,	₹€
The NEW ENGLAND JOURNAL of MEDICINE	
ORIGINAL ARTICLE	
Chemohormonal Therapy in Metast Hormone-Sensitive Prostate Cance	
Christopher J. Sweeney, M.B., B.S., Yu-Hui Chen, M.S., M.P.I	Н.,
	Articles
lition of docetaxel, zoledronic acid, or both to first-line g-term hormone therapy in prostate cancer (STAMPEDI vival results from an adaptive, multiarm, multistage, tform randomised controlled trial	@ `\@
	oa



AA+P+ADT vs ADT

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, M.D., Ph.D., NamPhuong Tran, M.D., Luis Fein, M.D.,

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

N.D. James, J.S. de Bono, M.R. Spears, N.W. Clarke, M.D. Mason,

What patient populations were included?

	ADT+AA	-P vs ADT	AD.	+Doce vs ADT	
	LATITUDE*1	STAMPEDE (Arm G) ^{2,3}	GETUG-AFU 15 ⁴	CHAARTED ^{5,6}	STAMPEDE (Arm C) ⁷
Total sample size, n	1199	1917	385	790	1776
Patients with mHSPC	100%	52%	100%	100%	61%
Patients with high- risk/high volume mHSPC	100%	NE	47.5% (183)	65 % (513)	NE
Patients with <i>de novo</i> M1	100%	49%	71%	72.8%	58%
Patients with visceral metastasis	17.3%	3%	14.5%	15.6%	3.8%
Patients with Gleason Score ≥8	98%	74.9%	56.1%	61.3%	70.1%
* All I ATITUDE patients ha	d high rick and ne	why disapsed mo	tactatic dicaaca		

* All LATITUDE patients had high-risk and newly diagnosed metastatic disease

NE, not evaluated



At least 2 of 3:

- ≥3 bone lesions
- Visceral metastasis
- Gleason score ≥8



At least 1 of 2:

- ≥4 bone lesions with
 ≥1 beyond the
 vertebral bodies/pelvis
- Visceral metastasis

Not head-to-head comparison studies

1. Fizazi K, et al. New England J Med. 2017 Jul 27;377(4):352-360; 2. James N, et al. ASCO 2017. LBA5003 and Oral Abstract Session; 3. James N, et al. New England J Med. 2017 Jul 27;377(4):338-351; 4. Gravis G, et al. Eur Urol. 2016 Aug;70(2):256-62; 5. Sweeney et al. N Eng J Med 2015; 378(8): 737-746; 6. Sweeney C, et al. Ann Oncol 2016;27(suppl 6):Abstract (and poster) 720PD; 7. James et al. Lancet 2016; 387(10024):1163-77

AA + P 5 mg QD in mHNPC: Detailed Safety Analyses From the LATITUDE Phase 3 Trial

The Majority of LATITUDE Patients Met the CHAARTED Definition for HV Disease

	AA + P + ADT	PBOs + ADT	Total
Overall population, n	597	602	1199
Patients with high-volume disease, ° n (%)	487 (82)	468 (78)	955 (80)
Patients with low-volume disease, n (%)	110 (18)	133 (22)	243 (20)
Unknown, ^b n (%)	0	1 (< 1)	1 (< 1)
^a Defined as the presence of visceral metastases and/or ≥ 4 be	one lesions with ≥1 outside of the	vertebral column and pelvis. ^b Due	to missing baseline scan.

Post hoc analyses

- General population
- High volume sec CHAARTED

Clinical Benefits in Patients With HV Disease Were Similar to Those Seen in the Overall Population

CHAARTED HV long term data

P value

0.0004

(95% CI)

(0.49 - 0.81)


	Patien high-volu	ts with me disease		ts with ne disease	Overall p	opulation
Clinical outcomes	AA + P + ADT n = 487	PBOs + ADT n = 468	AA+P+ADT n=110	PBOs + ADT n = 133	AA + P + ADT n = 597	PBOs + ADT n = 602°
Overall survival						
Median, months	NR	33.1	NR	NR	NR	34.7
HR (95% CI)	0.57 (0.4	16-0.71) ^ь	0.81 (0.4	48-1.34)°	0.62 (0.	51-0.76) ^d
-PFS ^e						
Median, months	30.7	14.7	NR	22.4	33.0	14.8
HR (95% CI)	0.43 (0.3	36-0.52) ^ь	0.53 (0.3	35-0.80) ^f	0.47 (0.3	39-0.55) ^d

STAMPEDE: ADT+AA+P vs ADT+DOC

STAMPEDE: Docetaxel vs abiraterone -- direct comparison 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 A Α B ·B С -OC + Dc--!-----D D **ESMO** F F 2017 Trial arm OC+Ab G ш SOC+M1|RT {M1} ----. - - - - - - - -Μ -M Pts in comparison Pts not in comparison ^ Abiraterone' # SOC+enzalutamide+abiraterone 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 566 patients randomised **Recruitment:** Nov-2011 to Mar-2013 **Patients:** 189 ADT+DOC 377 ADT+AA+P contemporaneously to either **Reported:** ESMO 2017 **Published:** (paper in development) research arm

AA+P = abiraterone acetate plus prednisone/prednisolone; ADT = androgen-deprivation therapy; DOC = docetaxel; SOC = standard of care (STAMPEDE terminology for ADT)

STAMPEDE: ADT+AA+P vs ADT+DOC






Figure 4. Depiction of disease state over time.

Table 3. Worst adverse event	(g	rade) re	portec	l over e	entire t	ime on	ı trial
------------------------------	----	----------	--------	----------	----------	--------	---------


SOC + Doc SOC + AAP (*n* = 189) (*n* = 377)

Safety population			
Number of patients included in analysis ^a	172	373	
Patients with an adverse event—no. (%)			
Grade 1–5 adverse event	172 (100)	370 (99)	
Grade 3–5 adverse event	86 (50)	180 (48)	
Grade 3–5 adverse events—no. (%)			
Endocrine disorder	15 (9)	49 (13)	
Febrile neutropenia	29 (17)	3 (1)	
Neutropenia (neutrophils)	22 (13)	4 (1)	
General disorder	18 (10)	21 (6)	
Fatigue	7 (4)	8 (2)	
Oedema	1 (1)	2 (1)	
Musculoskeletal disorder	9 (5)	33 (9)	
Cardiovascular disorder	6 (3)	32 (9)	
Hypertension	0 (0)	12 (3)	
Myocardial infarction	2 (1)	4 (1)	
Cardiac dysrhythmia	1 (1)	5 (1)	
Gastrointestinal disorder	9 (5)	28 (8)	
Hepatic disorder	1 (1)	32 (9)	
Increased AST	0 (0)	6 (2)	
Increased ALT	1 (1)	23 (6)	
Respiratory disorder	12 (7)	11 (3)	
Dyspnoea	4 (2)	1 (1)	
Renal disorder	5 (3)	20 (5)	
Lab abnormalities	9 (5)	11 (3)	
Hypokalaemia	0 (0)	3 (1)	

Sydes et al Annals Oncology 2018

LATITUDE vs CHARTEED: QL analysis

Mean Change in PRO Scores from Baseline for FACT-P (A) and BPI (B) from LATITUDE and CHAARTED



Feyerabend S, et al. Poster presented at ASCO-GU 2018; abstract 200.

Conclusion

✓ The LATITUDE and STAMPEDE trials open a new era in the management of M+ hormone naïve PCa

- ✓ Abiraterone + P add to ADT led to:
 - ✓ Significantly improved OS with a 37-38% reduction in the risk of death
 - ✓ More than 51% of study population is alive after 41 months
 - ✓ Significantly prolonged rPFS (53% reduction) and all secondary end points
 - ✓ Improve QoL, pain and fatigue as reported by patients
- Abiraterone is at least effective as Doc in management of patients with M+ Hormone naïve PCA

Take Home messages

- ✓ M+ Hormone naïve PCA:
 - ✓ Poor prognosis

✓ High-risk/high volume (at least 2 of the following: visceral metastases/ \ge 3 bone mets/ \ge GS8)

- Early treatment in M+ Hormone naïve PCa (within 3 months of ADT) is a new opportunity
- ✓ Further studies and real life data should confirm the best strategy to manage M+ Hormone naïve PCA according to patients 'preference and characteristics

Thank you!!!